Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02830477 · ClinicalTrials.gov registry record
Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 313
- Enrollment target
NCT02830477 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 313 participants.
The verdict
NCT02830477 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 313 participants
- Enrollment target
Study Summary
The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice. In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose \& dosing frequency, reason for choice of treatment regimen, FVIII product switch pattern, patient treatment satisfaction and adherence, KOVALTRY pharmacokinetic data (if performed), KOVALTRY consumption, as well as safety data.
Interventions
- BIOLOGICAL Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2016-10-14 |
| Est. Completion | 2021-03-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02830477
The ClinicalTrials.gov registry entry for NCT02830477 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973 is the first listed.
NCT02830477 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02830477 about?
NCT02830477 is a clinical study titled "Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis". The primary objective of this study is to investigate weekly prophylaxis dosing regimens used in standard clinical practice. In addition the study will capture reported bleed rate, pattern of change in KOVALTRY prophylaxis dose \& dosing frequency, reason for choice of treatment regimen, FVIII prod...
What is the current status of trial NCT02830477?
This trial is currently completed. The enrollment target is 313 participants. The study started on 2016-10-14. Estimated completion is 2021-03-01.
What interventions are being tested in trial NCT02830477?
The interventions under investigation include: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02830477?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.